Dihydroartemisinin + piperaquine

Section: 6. Anti-infective medicines > 6.5. Antiprotozoal medicines > 6.5.3. Antimalarial medicines > 6.5.3.1. Antimalarial medicines > Medicines for curative treatment

EMLc Codes ATC: P01BF05

Indication	Malaria due to Plasmodium vivax Code ICD11: 1F41
Type de médicament	Chemical agent
Type de liste	Liste de base
Formulations	**Oral > Solid > dispersible tablet:** 20 mg + 160 mg (phosphate) (EMLc) ; 40 mg + 320 mg (phosphate) (EMLc) **Oral > Solid > tablet:** 40 mg + 320 mg (phosphate) ; 20 mg + 160 mg (phosphate) ; 60 mg + 480 (phosphate) ; 80 mg + 640 mg (phosphate)
Historique des statuts LME	Ajouté pour la première fois en 2017 (TRS 1006) Modifié en 2025 (TRS 1064)
Sexe	Tous
Âge	Aussi recommandé pour les enfants
Équivalence thérapeutique	La recommandation concerne ce médicament spécifique
Renseignements sur le brevet	Patents have expired in most jurisdictions Lire la suite sur les brevets.
Wikipédia	Dihydroartemisinin + piperaquine
DrugBank	Artenimol, Piperaquine

Résumé des preuves et recommandation du comité d'experts

Following the review of the age-appropriateness of formulations on the EMLc, the Expert Committee recommended: - the addition of two new strengths of tablets (60mg + 480 mg and 80 mg + 840 mg) on the EML and EMLc; - the addition of two new strengths of dispersible tablets (20 mg + 160 mg and 40 mg + 320 mg) on the EMLc; - removal of the weight restriction, in recognition that use should be in line with recommendations with WHO guidelines; - to update the listing to include reference to the phosphate salt of piperaquine in the formulation description instead of the medicine name.